Day One BiopharmaceuticalsDAWN 12 Altman Z-Score is 18.80 as of Jun. 25, 2026, which is 129% above its 10-year median of 8.21. GuruFocus rates DAWN with a GF Score™ of 12/100. The stock has 5 warning signs investors should review. Among 935 Biotechnology companies, Day One Biopharmaceuticals ranks better than 87.38% on this metric.
The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.
Good Sign:
Altman Z-score of 18.8 is strong.
Day One Biopharmaceuticals has a Altman Z-Score of 18.80, indicating it is in Safe Zones. This implies the Altman Z-Score is strong.
The zones of discrimination were as such:
When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.
The historical rank and industry rank for Day One Biopharmaceuticals's Altman Z-Score or its related term are showing as below:
DAWN'
s Altman Z-Score Range Over the Past 10 Years
Min: 7.42 Med: 8.21 Max: 18.8
Current: 18.8
During the past 7 years, Day One Biopharmaceuticals's highest Altman Z-Score was 18.80. The lowest was 7.42. And the median was 8.21.
Day One Biopharmaceuticals (NAS:DAWN) Altman Z-Score Explanation
X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.
X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.
X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.
X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.
X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DAWN vs TYRA, DFTX, MLYS: Altman Z-Score Comparison
For the Biotechnology subindustry, Day One Biopharmaceuticals's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Day One Biopharmaceuticals Altman Z-Score vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Day One Biopharmaceuticals's Altman Z-Score distribution charts can be found below:
* The bar in red indicates where Day One Biopharmaceuticals's Altman Z-Score falls into.
Day One Biopharmaceuticals Altman Z-Score Calculation
Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.
Day One Biopharmaceuticals (DAWN) has a Altman Z-Score of 18.80 as of Jun. 25, 2026. The Altman Z-score measures a company's bankruptcy risk. View historical data on Day One Biopharmaceuticals and its competitors. This is 129% above median its historical median of 8.21. Over the past decade, Day One Biopharmaceuticals' Altman Z-Score has ranged from 7.42 to 18.80. According to the industry distribution chart, Day One Biopharmaceuticals ranks #118 out of 935 companies in the Biotechnology industry, placing it in the top 12.6%.
Is Day One Biopharmaceuticals' Altman Z-Score too high?
Day One Biopharmaceuticals' current Altman Z-Score of 18.80 is 129% above median its 10-year median of 8.21. Over the past 10 years, this metric has ranged from a low of 7.42 to a high of 18.80. The Biotechnology industry median Altman Z-Score is 2.64. Day One Biopharmaceuticals' value of 18.80 is 612.1% above this industry median. Based on the distribution chart, Day One Biopharmaceuticals ranks #118 out of 935 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Day One Biopharmaceuticals has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Day One Biopharmaceuticals' Altman Z-Score compare to TYRA and DFTX?
According to the Biotechnology industry distribution chart, Day One Biopharmaceuticals ranks #118 out of 935 companies for Altman Z-Score. This places Day One Biopharmaceuticals in the top 13% of its industry — outperforming the majority of peers. The industry median Altman Z-Score is 2.64. Day One Biopharmaceuticals' value of 18.80 is 612.1% above this benchmark. Historically, Day One Biopharmaceuticals' own Altman Z-Score has ranged from 7.42 to 18.80 over the past decade. While the company's 10-year median is 8.21 vs. the industry median of 2.64, Day One Biopharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z-Score for a Biotechnology company?
The median Altman Z-Score among Biotechnology companies is 2.64, based on 935 companies in the industry. Companies in the top quartile (top 25%) have a Altman Z-Score significantly above this median, while those in the bottom quartile fall well below. However, Altman Z-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Day One Biopharmaceuticals's current Altman Z-Score of 18.80 is 612.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z-Score mean?
A high Altman Z-Score can signal that a stock is expensive relative to its fundamentals. The Altman Z-score measures a company's bankruptcy risk. View historical data on Day One Biopharmaceuticals and its competitors. For the Biotechnology industry, the median Altman Z-Score is 2.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Day One Biopharmaceuticals's current Altman Z-Score is 18.80, which is 129% above median its own 10-year median of 8.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Day One Biopharmaceuticals stock overvalued right now?
Day One Biopharmaceuticals (DAWN) has a current Altman Z-Score of 18.80. The current Altman Z-Score is 18.80, which is 129% above median its 10-year median of 8.21 and 612.1% above the Biotechnology industry median of 2.64. Day One Biopharmaceuticals' overall GF Score™ is 12/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z-Score calculated?
Altman Z-Score is calculated from a company's financial statements. For Day One Biopharmaceuticals (DAWN), the current Altman Z-Score is 18.80 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY301 is an antibody drug conjugate (ADC) that has shown antitumor activity in preclinical models.
12GF Score
Get the complete analysis for DAWN
Altman Z-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DAWN has been successfully added to your 
